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Adenosine can induce vasodilatation and vasoconstriction of
the renal afferent arteriole of the mouse. We determined here
its direct effect on efferent arterioles of mouse kidneys. Using
isolated-perfused cortical efferent arterioles, we measured
changes in luminal diameter in response to adenosine.
Extraluminal application of adenosine and
cyclohexyladenosine had no effect on the luminal diameter.
When the vessels were constricted by the thromboxane
mimetic U46619, application of adenosine and
50-N-ethylcarboxamido-adenosine dilated the efferent
arterioles in a dose-dependent manner. We also found
that the adenosine-induced vasodilatation was
inhibited by the A2-specific receptor blocker 3,7-dimethyl-
1-propargylxanthine. In the presence of this inhibitor,
adenosine failed to alter the basal vessel diameter of
quiescent efferent arterioles. Using primer-specific
polymerase chain reaction we found that the adenosine A1,
A2a, A2b, and A3 receptors were expressed in microdissected
mouse efferent arterioles. We conclude that adenosine
dilates the efferent arteriole using the A2 receptor subtype
at concentrations compatible with activation of the A2b
receptor.
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The resistance vessels in the kidney include afferent and
efferent glomerular arterioles. Changes in their resistances
regulate renal blood flow and are important determinants of
glomerular ultrafiltration pressure and glomerular filtration
rate. The afferent arteriolar resistance is modulated by
changes in adenosine concentration. Thus, the nucleoside
has been held responsible for the afferent arteriolar constric-
tion in response to an increased NaCl concentration at the
macula densa that underlies the tubuloglomerular feedback
(TGF) mechanism.1–4 An increased NaCl concentration at the
macula densa leads to release of adenosinetriphosphate5
followed by interstitial conversion to adenosine through
50-ectonuclotidase.6 The ability of adenosine to constrict the
renal afferent arteriole through activation of adenosine A1
receptors (A1AR) is well established.
7–12 By contrast,
the effects of adenosine on the efferent arteriole are
controversial.13
Adenosine in the interstitium initiates its effects by
activating members of the P1 class of purinergic receptors.
P1 receptors are G-protein-coupled receptors with seven
membrane-spanning domains.14 Four members of the P1
receptor family have been identified, designated A1, A2a, A2b,
and A3 adenosine receptors, and all four receptor subtypes
are expressed in the rat kidney.15,16 In the renal vasculature,
the presence of A1AR has been demonstrated in preglomer-
ular resistance vessels both at the mRNA and protein
levels.17–19 Furthermore, adenosine A2 receptors (A2AR) are
expressed in preglomerular vessels although it is unclear
whether both A2aAR and A2bAR are present.
19,20 The
response to adenosine in the afferent arteriole therefore
reflects a net effect of competing influences resulting from the
concomitant activation of A1AR and A2AR. The precise
identity of adenosine receptors in efferent arterioles is
controversial.
Adenosine elicits marked dilatations in most vascular beds
that are mediated by A2a (high-affinity) and A2b (low-
affinity) receptors coupled to Gs proteins.14 This is in
contrast to the adenosine-mediated constriction at low
concentrations observed in the afferent arteriole, which is
elicited by A1AR activation coupled to Gi proteins. The
increase in adenosine concentration in the interstitium of the
juxtaglomerular apparatus during TGF adjustments could
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potentially affect the efferent arteriole.6,21 Therefore, the
present experiments were designed to determine the direct
functional response to adenosine of isolated perfused efferent
arterioles from mice and the nature of the adenosine
receptors involved.
RESULTS
Cumulative concentration–response curves to adenosine and
cyclohexyladenosine in quiescent preparations
No significant change in blood vessel diameter could be
observed after application of increasing concentrations of
adenosine (Figure 1a). A second sequence of adenosine
application also failed to cause significant changes in
diameter (data not shown). The luminal diameter was not
affected significantly by the application of the A1AR agonist
cyclohexyladenosine (CHA) (Figure 1b).
Constrictions to U46619
U46619 constricted the efferent arterioles from 3.5±0.2 to
3.0±0.3 mm (2 108 mol/l) to 0.1±0.1 mm (107 mol/l)
(Figure 2a). Repeated application of U46619 (107 mol/l)
caused maximal and reproducible (data not shown) tonic
constrictions of the efferent arterioles for 21 min (the time
frame required for six consecutive applications of adenosine)
(Figure 2b). Photographs of a perfused efferent arteriole with
and without U46619 are shown in Figure 2c and d.
Cumulative concentration–response curve to adenosine
and the A2AR agonist 5
0-(N-ethylcarboxamido)-adenosine
in constricted preparations
In efferent arterioles constricted with U46619,
109–108 mol/l adenosine did not have a significant effect,
whereas higher concentrations dilated the vessels in a
concentration-dependent manner; a statistically significant
and reproducible dilatation was reached at 105 mol/l
adenosine (Figure 3a). In the first application sequence basal
diameter was 5.9±0.7 mm, and 107 mol/l U46619 reduced
vessel diameter to 0.0±0.0 mm. During the first application
sequence, addition of 104 mol/l adenosine increased the
diameter to 5.0±0.3 mm, which corresponds to 87±7% of
the basal diameter. After washout, the basal diameter
averaged 6.3±0.8 mm. In the second application series,
107 mol/l U46619 reduced vessel diameter to 0.2±0.2 mm,
and addition of 104 mol/l adenosine reversed the constric-
tion to 5.7±0.7 mm, which is 92±7% of second application
basal diameter. The effect of adenosine was reproducible
(Figure 3a). The EC50 for adenosine averaged 7.0 106 and
1.3 106 mol/l for the first and second application
sequences, respectively. These values were not significantly
different. Vessels preconstricted with U46619 dilated dose
dependently after application of 50-(N-ethylcarboxamido)-
adenosine (NECA) (Figure 3b, Po0.05). The EC50 for NECA
was 5.2 108 mol/l.
Inhibition by the A2AR antagonist DMPX
Under control conditions, adenosine caused a concentration-
dependent increase in luminal diameter in U46619-
constricted vessels, with an EC50 of 1.4 106 mol/l.
3,7-Dimethyl-1-propargylxanthine (DMPX) (104 mol/l)
did not significantly change the resting luminal diameter
(from 5.1±0.6 to 5.1±0.7 mm). After incubation with
DMPX (10–4 mol/l), the addition of 107 mol/l U46619 still
constricted the vessels to 0.7±0.7 mm but the addition of
increasing concentrations of adenosine did not significantly
alter the arteriolar diameter (Figure 4).
A single injection of 107 mol/l of adenosine did not
change the diameter of quiescent efferent arterioles (Figure 5).
After incubation with DMPX, adenosine did not induce
significant changes in diameter (Figure 5).
RT–PCR
The reverse transcriptase–PCR (RT–PCR) analysis showed
bands of the expected size for A1AR, A2aAR, A2bAR, and
A3AR in superficial efferent arterioles and in the positive
control using whole kidney (Figure 6a). The negative
controls, water and –RT, showed no bands. The presence of
A1AR, A2aAR, A2bAR, and A3AR was also detected in
microdissected afferent arterioles (Figure 6b).
DISCUSSION
This study shows for the first time the direct effect of
adenosine on cortical efferent arterioles of the mouse
perfused in vitro. The findings demonstrate that adenosine
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Figure 1 | Concentration–response relationship for adenosine
(ado) and CHA in mouse superficial efferent arterioles. (a)
Adenosine was administered to the bath solution every third
minute in cumulatively increasing concentrations. Data are
means±s.e.m. (n¼ 5). (b) Increasing concentrations of CHA
applied to the bath solution. Data are means±s.e.m. (n¼ 5).
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and the A2AR agonist NECA elicit a concentration-depen-
dent dilatation in constricted preparations whereas the
nucleoside and the A2AR agonist CHA did not change the
luminal diameter of quiescent blood vessels. The ability of
A2AR antagonist DMPX to inhibit the dilatation suggests that
the relaxation is mediated by activation of A2 adenosine
receptors.22 All four known subtypes of adenosine receptors
were expressed in both pre- and postglomerular arterioles. In
resemblance to the afferent arteriole, the net effect of
adenosine on the efferent arteriole could reflect competing
activation of A1AR and A2AR. However, in contrast to the
afferent arteriole, the main effect of adenosine on the efferent
arteriole is vasodilatation. This direct evidence for dilatation
of cortical efferent arterioles by adenosine is in agreement
with the overall suggested vascular effect for the nucleoside.
Indeed, adenosine elicits a decrease in filtration fraction23,24
that is consistent with a dilatation in the postglomerular
arterioles. Furthermore, an adenosine-induced dilatation has
been observed in efferent arterioles of hydronephrotic kidney
of the rat.8,25
The thromboxane analogue U446619 caused a
concentration-dependent constriction of the efferent
arterioles and led to sustained constriction over time, making
it well suitable for the study of dilator responses in this
preparation. In this study, the EC100 concentration of the
thromboxane-prostanoid agonist was used, as lower levels of
constriction would lead to a magnitude of dilatation that
would be difficult to measure accurately in view of the small
size of the preparation.
Both adenosine and the A2AR agonist NECA dilated the
efferent arterioles by 80% after complete closure with
U46619. This effect is in agreement with several studies
showing the ability of adenosine and adenosine receptor
agonists to dilate postglomerular vessels.8,25 Thus, Holz and
Steinhausen25 reported that in the hydronephrotic kidney of
the rat the adenosine receptor agonist NECA induces a small
efferent dilatation and an increase in glomerular blood flow.
In the same preparation, adenosine increased the diameter of
the efferent arteriole by 14%, and the dilatation was abolished
by the A2AR blocker DMPX.
8
The vasodilatation observed in this study can be attributed
to activation by adenosine of A2AR. This conclusion is based
on the observation that DMPX abolished the response and
that NECA elicited a vasodilatation similar to the adenosine-
induced effect. DMPX is a nonselective A2AR antagonist and
thus the present observations do not provide further evidence
for the involvement of A2AR subtypes. Because the A2bAR
subtype is a low-affinity receptor, it is likely responsible for
the observed efferent dilatation caused by adenosine, as high
concentrations of adenosine were necessary to elicit the
response. In addition to a receptor-mediated effect, an
intracellular action of adenosine may also affect afferent
arteriolar tone.26 However, in whole kidney experiments,
inhibition of nucleoside transport reduces glomerular filtra-
tion rate with an insignificant decrease in renal vascular
resistance, which is consistent with an increase in efferent
arteriolar diameter.27 Because the effect after nucleoside
transport inhibition was blocked completely by DMPX,
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Figure 2 | Effect of the thromboxane receptor agonist U46619 in mouse superficial efferent arterioles. (a) Cumulatively increasing
concentrations of U46619 were added to the bath every third minute. Full constriction was seen with 107 mol/l. Basal diameter (Basal)
before U46619 administration is set to 100%. Data are means±s.e.m. (n¼ 5). (b) Application of 107 mol/l U46619 for 21 min. Each arrow
represents bath substitution with new medium containing 107 mol/l U46619. Data are means±s.e.m. (n¼ 3). (c) Photograph of an isolated
perfused mouse efferent arteriole under basal conditions. (d) Efferent arteriole constricted with U46619 (107 mol/l).
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the response was mediated most likely by A2AR activation
in response to an increased adenosine concentration
in the interstitium. Whether nucleoside transport is involved
in the adenosine-elicited response in the efferent arteriole
is unknown.
The application of adenosine in quiescent cortical efferent
arterioles did not change the luminal diameter at any
concentration. By contrast, in the in vitro blood-perfused
juxtamedullary nephron preparation, adenosine evokes a
biphasic response of efferent arterioles with constriction at
concentrations in the micromolar range and dilatation at
higher doses.7,9 The vasoconstrictor component of this
biphasic response has been attributed to activation of
A1AR. Likewise, in afferent arterioles, A1AR are responsible
for the constriction elicited by adenosine,12,28 and in the
blood-perfused rat juxtamedullary nephron preparation low
concentrations of adenosine decrease afferent arteriolar
diameter, an effect that is enhanced by DMPX.29 In the
present experiments, DMPX, at the same concentration
which inhibited adenosine-elicited vasodilatation, did not
unmask changes in diameter in quiescent efferent arterioles.
Because adenosine potentially could be metabolized during
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Figure 3 | Reproducible concentration–dilatation curves to
adenosine (ado) and NECA in arterioles constricted with
U46619. ‘Basal’ represents basal vessel diameters before
application of adenosine or NECA. (a) Adenosine was added to
the bath solution every third minute in cumulatively increasing
concentrations. Data are means±s.e.m. (n¼ 4; *Po0.05 vs
U46619). (b) Increasing concentrations of NECA applied to the
bath every third minute. Data are means±s.e.m. (n¼ 5).
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Figure 4 | Concentration–response relationship for adenosine
(ado) in arterioles constricted with U46619 in the absence
(left) and presence (right) of DMPX. Data are means±s.e.m.
(n¼ 5; *Po0.001 vs U46619).
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Figure 5 | Effect of adenosine (ado) in the presence of the A2AR
antagonist DMPX. The plot shows diameter of the same blood
vessel during adenosine application before and after treatment
with DMPX. Diameters for each application are expressed as
percent of vessel diameter before treatment. Data are
means±s.e.m. (n¼ 8; P40.05 for ado vs DMPXþ ado).
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Figure 6 | Expression of adenosine receptors in mouse
superficial arterioles. Bands of the expected size were obtained
for A1AR, A2aAR, A2bAR, and A3AR in efferent arterioles (Eff. art., a),
afferent arterioles (Aff. art., b), and in the positive control using
whole kidney. The negative control, water, expressed no bands.
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the experiment, we used the nonmetabolized A1AR agonist
CHA. This drug also had no effect on luminal diameter.
Taken in conjunction, these findings show that activation of
A1AR does not contribute to the cortical efferent arteriolar
responses to adenosine in the mouse. The discrepancy
between the effects of adenosine on cortical efferent arterioles
in this study and those observed in juxtamedullary efferent
arterioles7,9 could be due to differences in species and
preparation studied. However, it potentially adds further
evidence to the view that juxtamedullary efferent arterioles
differ from the corresponding cortical preparations.30,31
Changes in the efferent and afferent arteriole diameters
regulate renal blood flow and glomerular filtration rate.
Efferent arterioles in vivo possess tone. The present in vitro
observation of a tone-dependent vasodilator effect of
adenosine mediated by A2AR may be relevant for the fall
in efferent resistance induced by adenosine in vivo in
situations with decreased glomerular capillary pressure and
filtration rate. Furthermore, in addition to the well-
documented afferent arteriolar vasoconstrictor response,32
efferent vasodilatation may be involved in the TGF mechan-
ism.21,33 Thus, in the isolated perfused juxtaglomerular
apparatus, increasing the NaCl concentration at the macula
densa dilates the efferent arteriole significantly. This increase
in diameter can be blocked by an A2AR antagonist and by
preventing extracellular adenosine formation. Therefore, the
direct response to high concentrations of adenosine observed
in this study implies that the dilatation in response to high
NaCl concentrations in the macula densa21,33 could be due to
release of high concentrations of adenosine with a subsequent
dilatation. In support of this interpretation, micropuncture
studies reveal that activation of the TGF and the resulting
decrease in glomerular filtration rate occur with simulta-
neous decreased or unchanged glomerular capillary pres-
sure.34 A role for an adenosine-mediated vasodilatation of
the efferent arteriole during activation of the TGF could
potentially explain in part the decreased glomerular capillary
pressure.
Several studies have investigated the distribution of
adenosine receptors in the kidney but the precise localization
of these receptors in the renal glomerular vessels is still
unclear. This study demonstrates the expression of A1AR,
A2aAR, and A2bAR mRNA in microdissected efferent
arterioles. The expression of A1AR and A2aAR in mouse
glomerular arterioles has also been observed by Vitzthum
et al.20 although these authors did not detect A2bAR in mouse
glomerular vessels. Functional data by Lai et al.34 suggest the
existence of low-affinity adenosine receptors A2bAR in mice
afferent arterioles. Existence of A2bAR on preglomerular
vessels is established in the rat.10,19,20 For postglomerular
vessels only Kreisberg et al.35 have determined the expression
of adenosine receptors in the outer medullary vasa recta.
In conclusion, this study provides evidence for the
expression of the four known subtypes of adenosine receptors
in efferent arterioles of the mouse. In constricted vessels,
which are most relevant for the in vivo situation, adenosine
elicits efferent vasodilatation, through A2AR activation. This
vasodilatation elicited by adenosine could be relevant for the
regulation of efferent arteriolar diameter during activation of
the TGF.
MATERIALS AND METHODS
Animals
The investigation conformed with the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of
Health. The C57BL/6 mice used in this study had free access to
rodent chow (Altromin, Lage, Germany) and tap water.
Perfused cortical efferent arterioles
Efferent arterioles with attached glomeruli were microdissected at
4 1C in DMEM/F12 from mice of either sex (17–27 g) and were
perfused retrogradely. The method was similar to the perfusion
technique described by Hansen et al.12 but adapted to efferent
arterioles. Efferent arterioles were identified by the following
criteria; they are thinner than the afferent arteriole, they often are
curved as opposed to the straight afferent arterioles, and they divide
into capillaries. Furthermore, we used the paths of the preglomer-
ular vasculature for comparison. The efferent arteriole with its
glomerulus intact (afferent arteriole removed by cutting the vessel
close to the glomerulus) was transferred to a thermostated (37 1C)
perfusion chamber (Warner), mounted on an inverted microscope
(Zeiss Axiovert 10). The segment was perfused by aspiration of the
arteriole into a holding pipette (tip diameter 14 mm) followed by
cannulation with a perfusion pipette (tip diameter 4–5 mm) and
increase in driving pressure until the vessel opened, indicating
attained perfusion. The entire experiment was recorded using a
digital camera (DAGE MTI). One frame per second was stored on a
computer, using a frame grabber card (Pixel Smart).
The dose–response curve to adenosine was determined in the
concentration range of 109 to 103 mol/l. Each concentration
(added extraluminally to the bath) was in contact with the
preparations during 3 min each. After a washout period the above
was repeated. The same protocol was repeated using the A1AR
agonist CHA. Concentration–response curves were obtained also
for the thromboxane-prostanoid receptor agonist U46619
(9,11-dideoxy-11a,9a-epoxymethanoprostaglandin F2a) by adding
the compound to the bath for 3 min at increasing concentrations
(2 108–107 mol/l; 3 min exposure to each concentration). To
obtain sustained constrictions of the efferent arterioles, U46619
(107 mol/l) was added repeatedly to the bath at 3 min intervals for
a total of 21 min.
Increasing concentrations of adenosine (109–104 mol/l) were
administered at 3 min intervals minute during sustained U46619-
induced constrictions. This protocol was repeated using the A2AR
agonist NECA.
The A2AR antagonist DMPX (10
4 mol/l) was added to the bath
for a period of 15 min before determining the response to adenosine
during sustained U46619-induced constrictions. The effect of
DMPX was also tested on the response to adenosine (107 mol/l)
in quiescent preparations.
Data analysis
Images were transferred to a custom-made imaging software DiaFix
(produced by Rozh Husain Al-Mashhadi, University of Southern
Denmark). Luminal (interendothelial) blood vessel diameters were
measured on the computer screen using images of interest. To
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eliminate bias, a randomization algorithm was coded in the software
utility, allowing blinded measurements of diameter. Luminal
diameter was determined at the most reactive part of the arteriole.
Statistical analysis
All data are expressed as means±s.e.m. Blood vessel diameters are
expressed in percent of basal. Bartlett’s test for equal variances was
used to verify that the variances did not differ significantly, thereby
allowing for analysis of variance. Further analysis was conducted
using one-way analysis of variance followed by Bonferroni’s multiple
comparison test, two-way analysis of variance or the paired t-test.
P-values less than 0.05 were considered to indicate statistically
significant differences.
Isolation of cortical efferent arterioles for PCR analysis
Mice were killed by cervical dislocation and the kidneys were
removed and placed on ice. Kidney slices were digested using
enzyme treatment containing collagenase NB8, 0.5 g/l (Serva,
Heidelberg, Germany); trypsin inhibitor, 0.1 g/l (Sigma, St. Louis,
MO, USA); dispase II, 0.35 g/l (Roche, Basel, Switzerland); and
DNAse I, 1.8 ml/l (Roche) for 45 min at 37 1C. Using a sharpened
forceps, microdissection of cortical efferent arterioles was performed
under a stereomicroscope. Arterioles with glomeruli were moved to
a clean Petri dish and the efferent arterioles were cut from the
glomeruli. Isolated efferent arterioles were then collected for PCR.
RT–PCR
RNA was isolated from microdissected efferent arterioles and reverse
transcribed using Superscript and oligo as described previously.36
Double PCR was performed for 30 cycles using template from three
efferent arterioles per PCR reaction. One-third of the PCR product
was used in the second PCR reaction running for 34 cycles. Specific
mouse primers were—A1AR: forward primer, 5
0-cag-agc-tcc-atc-
ctg-gct-ct-30, reverse, 50-cgc-tga-gtc-acc-act-gtc-ttg-30 covering 100
base pairs (GenBank accession no. NM 001008533); A2aAR: forward
primer, 50-ggc-tat-tgc-cat-cga-cag-at-30, reverse, 50-agg-tag-atg-gcc-
agc-atg-ag-30 covering 300 base pairs (GenBank accession no.
Y13346); A2bAR: forward primer, 5
0-cgg-gat-cct-ttc-acg-gct-gcc-tct-
tc-30, reverse, 50-gga-att-cca-tcc-ccc-agt-tct-gtg-c-30 covering 256
base pairs (GenBank accession no. GI6680655) from Vitzthum
et al.;20 and A3AR: forward primer, 5
0-acc-gat-acc-tgc-ggg-tca-a-30,
reverse, 50-tca-gcc-cca-cca-gaa-agg-30 covering 111 base pairs
(GenBank accession no. AF069778). Negative controls included
water and RNA where no reverse transcriptase was added to the
reaction (RT). Whole kidney tissue was used as a positive control.
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